Table of Contents
Eating Disorder Treatment Market Overview
Bulimia and eating disorder treatment companies provide a holistic approach that addresses the psychological, medical, and nutritional issues related to disorders like anorexia, bulimia, and binge eating.
It typically involves a multidisciplinary team that conducts comprehensive assessments and utilizes cognitive behavioral and family-based therapies.
Nutritional rehabilitation aims to restore healthy eating habits, often with the help of registered dietitians. Medical management may include medications and regular health monitoring.
Support groups and ongoing aftercare are vital for sustained recovery. Early intervention and personalized treatment strategies are key to improving outcomes and reducing health risks.
Market Drivers
The global eating disorder treatment market is driven by several key factors, including the rising prevalence of eating disorders. Particularly among adolescents, and increased awareness of mental health issues.
The effectiveness of advanced treatment modalities, such as cognitive behavioral therapy, enhances patient engagement.
Improved healthcare infrastructure and government initiatives promote access to specialized care while integrating telehealth services expands treatment availability.
Additionally, the focus on personalized treatment plans and early intervention strategies further drives market growth. Reflecting a societal shift towards prioritizing mental health and wellness.
Market Size
The global virtual eating disorder treatment market is expected to grow from USD 836.1 million in 2023 to approximately USD 2,072.0 million by 2033, achieving a CAGR of 9.5% from 2024 to 2033.
List of Major Companies
These are the top ten companies operating in the Eating Disorder Treatment Market:
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories is actively engaged in the healthcare sector, focusing on advancements that support bulimia and eating disorder treatment companies.
Its strong nutritional brand, Ensure, plays a crucial role in nutritional rehabilitation for recovery. In 2023, Abbott reported a 13.9% organic growth in adult and pediatric nutrition sales, underscoring its market leadership.
The $890 million acquisition of Cardiovascular Systems, Inc. further enhances its medical device portfolio in cardiovascular care.
Aligning with broader health initiatives for eating disorder treatment. Abbott’s advancements in diagnostics also address the rising need for early and accurate diagnoses of health conditions.
Including eating disorders, reflecting its strategic focus on innovation and expansion through acquisitions and product launches.
Geographical Presence
Abbott Laboratories operates in over 160 countries, allowing it to serve diverse markets effectively. In North America, the focus is on diagnostics and nutrition, particularly in the U.S. and Canada.
Key European markets include Germany, France, and the UK, emphasizing medical devices and cardiovascular products.
The Asia-Pacific region, especially China and India, offers growth opportunities through tailored healthcare solutions.
In Latin America, Brazil and Mexico are central for diagnostics and nutrition. At the same time, the UAE serves as a hub for the Middle East and Africa, with expansion efforts in South Africa.
Overall, Abbott’s strategic approach and diversified portfolio drive its growth and competitive edge in the global healthcare sector.
Recent Developments
- In October 2024, Abbott terminated the sale of a 51% stake to The Searle Company Limited.
- In September 2023, Abbott’s acquisition of Bigfoot Biomedical enhanced its diabetes market position and complemented its FreeStyle Libre® continuous glucose monitoring technology.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck is involved in the bulimia and eating disorder treatment companies/market by focusing on related areas like mental health and gastrointestinal conditions.
Its acquisition of Prometheus Biosciences for $10.8 billion in 2023 strengthened its immunology portfolio, particularly with treatments for inflammatory bowel diseases that intersect with gastrointestinal issues in eating disorders.
Additionally, Merck is expanding its neuroscience portfolio with a gefapixant for chronic cough and MK-8189 for schizophrenia.
These efforts reflect Merck’s commitment to enhancing mental health and wellness treatments, demonstrating its dedication to improving options across various medical conditions that may benefit patients in related areas.
Geographical Presence
Merck & Co., Inc., or MSD outside North America, has a strong global presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
The U.S. is its largest market, driven by a diverse portfolio of pharmaceuticals and vaccines. In Europe, Merck focuses on local healthcare partnerships in both Western and Eastern markets.
Key areas in Asia-Pacific include China and Japan, while Brazil and Mexico are vital in Latin America. In the Middle East and Africa, particularly in South Africa and the GCC countries, Merck is expanding to meet increasing healthcare demands.
Through strategic investments, the company aims to address unique market challenges and enhance its global leadership in healthcare.
Recent Developments
- In October 2024, Merck entered a licensing and collaboration agreement with Mestag Therapeutics to develop innovative fibroblast therapies for inflammatory diseases.
- In October 2024, Merck acquired CN201, an innovative bispecific antibody in clinical trials for B-cell-related diseases.
GSK
Company Overview
| Establishment Year | 2000 |
| Headquarter | London, England, UK |
| Key Management | Emma Walmsley (CEO) |
| Revenue (US$ Bn) | $ 37.7 Billion (2022) |
| Headcount | ~ 70,000 (2024) |
| Website | https://www.gsk.com/ |
About GSK
GSK plc is involved in areas relevant to bulimia and eating disorder treatment companies, such as mental health, immunology, and nutrition.
In 2023, the company expanded its product offerings, particularly in vaccines and specialty medicines, including a partnership with Zhifei to co-promote the shingles vaccine Shingrix in China, aimed at improving global preventive healthcare access.
GSK’s acquisition of TESARO enhances its oncology portfolio, addressing cancer-related health issues, including malnutrition associated with disorders like anorexia.
While not directly focused on eating disorders, GSK’s advancements in related fields support better management of interconnected mental and physical health challenges.
Geographical Presence
GSK plc (GlaxoSmithKline) has a strong global presence, particularly in North America, where it focuses on pharmaceuticals, vaccines, and consumer healthcare in the U.S. and Canada.
Its European headquarters in the UK leads extensive R&D, supported by operations in France, Germany, Italy, and Spain. In the Asia-Pacific region, GSK targets healthcare needs in China, India, Japan, and Australia.
The company is also significant in Brazil, Mexico, and Latin America. It is expanding its footprint in the Middle East and Africa to enhance access to vaccines and essential medicines.
This broad geographical presence allows GSK to leverage local expertise and maintain its leadership in the pharmaceutical and biotechnology industries.
Recent Development
- In October 2024, GSK partnered with researchers from Boston University and Boston Medical Center to develop new models for studying lung diseases like pulmonary fibrosis.
- In January 2024, GSK acquired Aiolos to access AIO-001, a long-acting TSLP monoclonal antibody in phase II development for adult asthma and chronic rhinosinusitis.
Novartis
Company Overview
| Establishment Year | 1996 |
| Headquarter | Basel, Switzerland |
| Key Management | Vasant Narasimhan (CEO) |
| Revenue (US$ Bn) | $ 45.4 Billion (2023) |
| Headcount | ~ 76,057 (2023) |
| Website | https://novartis.com/ |
About Novartis
Novartis AG’s focus on neuroscience and related areas has some implications for mental health conditions, including bulimia and eating disorder treatment companies.
In 2023, Novartis acquired DTx Pharma, a biotechnology company working on RNA-based therapies for neurological disorders, which strengthened its position in neuroscience research.
Additionally, Novartis continues to innovate through acquisitions such as Chinook Therapeutics, which is focused on precision medicines, demonstrating the company’s commitment to advancing treatments in complex health conditions.
These developments align with their broader strategy to focus on neuroscience and immunology, areas that indirectly impact mental health treatments.
Geographical Presence
Novartis AG, based in Switzerland, operates globally and plays a significant role in market dynamics. North America, particularly the U.S., boasts a robust pharmaceutical portfolio, while Europe, especially Germany and the UK, is key for its innovations.
The company is also targeting growth in the Asia-Pacific region, focusing on China and India and addressing healthcare needs in emerging markets like Brazil and Mexico.
Additionally, Novartis is enhancing access to essential medicines in Africa and the Middle East. With strategic regulatory navigation and strong investment in research and development, Novartis is well-positioned to meet global healthcare demands and capitalize on growth opportunities.
Recent Development
- In September 2024, Novartis sold Worldwide Rights to DESFERAL (deferoxamine) to MITEM Pharma.
- In July 2023, Novartis acquired DTx Pharma, a San Diego preclinical biotech firm developing siRNA therapies for neuroscience using its FALCON platform.
Johnson-n-Johnson
Company Overview
| Establishment Year | 1886 |
| Headquarter | New Brunswick, New Jersey, U.S. |
| Key Management | Joaquin Duato (CEO) |
| Revenue (US$ Bn) | $ 85.1 B (2023) |
| Headcount | ~ 134,400 (2023) |
| Website | https://www.jnj.com/ |
About Johnson & Johnson
Johnson & Johnson’s work in neuroscience and mental health has tangential benefits for treating eating disorders.
J&J has been strengthening its neuroscience portfolio, which could impact the development of treatments for mental health disorders, including those associated with eating disorders.
In 2023 and 2024, J&J made significant moves, such as acquiring Ambrx Biopharma, which advances antibody-drug conjugates (ADCs) in oncology, and continuing investments in immunology and neuroscience.
These strategic acquisitions could indirectly support therapeutic approaches to mental health, including anxiety and depression, which often co-occur with eating disorders.
The company’s overall push to innovate across mental health and neurobiological disorders positions it to contribute to areas related to the treatment of eating disorders.
Geographical Presence
Johnson & Johnson (J&J) is a multinational corporation with a diverse portfolio in pharmaceuticals, medical devices, and consumer health products.
The company has a strong presence in North America, particularly the U.S. and Canada, supported by local manufacturing and R&D. In Europe, J&J is expanding in both Western and Eastern markets.
The Asia-Pacific region, especially China and India, is vital for growth, along with increasing activities in Southeast Asia.
Latin America, particularly Brazil and Mexico, and enhanced operations in Africa and the Middle East are also focus areas. J&J’s strategy prioritizes localized operations and innovation to drive growth in emerging markets.
Recent Developments
- In October 2024, J&J launched the VOLT Variable Angle Optimized Locking Technology Plating System.
- In January 2024, J&J acquired Ambrx Biopharma, a clinical-stage company specializing in synthetic biology for next-generation antibody-drug conjugates (ADCs).
Bristol-Myers
Company Overview
| Establishment Year | 1887 |
| Headquarter | Princeton, New Jersey, U.S. |
| Key Management | Chris Boerner (CEO) |
| Revenue (US$ Bn) | $ 45.01 Billion (2023) |
| Headcount | ~ 34,000 (2023) |
| Website | http://bms.com/ |
About Bristol Myers Squibb
Bristol Myers Squibb (BMS) has made strides in areas such as neuroscience and mental health, which are relevant to bulimia and eating disorder treatment companies.
In 2023, BMS strengthened its neuroscience portfolio with the acquisition of Karuna Therapeutics, which is developing KarXT, a novel antipsychotic aimed at treating schizophrenia and Alzheimer ‘s-related psychosis.
These conditions often intersect with mental health issues like anxiety and depression, which are frequently co-occurring in individuals with eating disorders.
Additionally, BMS has been expanding its oncology and immunology portfolios through significant acquisitions, including the purchase of RayzeBio, which enhances its pipeline in radiopharmaceuticals.
These strategic moves indicate BMS’s growing influence in areas that can contribute to overall mental and physical health, indirectly supporting the broader mental health landscape.
Geographical Presence
Bristol Myers Squibb (BMS) has a robust global presence, particularly in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
The U.S. is its largest market, with Canada and Western Europe also contributing significantly through local operations.
In the Asia-Pacific region, BMS focuses on China and Japan, investing in research and local partnerships. The company is expanding in Latin America, especially in Brazil and Mexico, while also exploring opportunities in the Middle East and Africa to improve access to its therapies.
This strategic approach enables BMS to meet diverse healthcare needs and regulatory requirements, furthering its mission to provide transformative medicines worldwide.
Recent Developments
- In October 2024, BMS received FDA approval for Opdivo to treat adults with resectable non-small cell lung cancer.
- In September 2024, BMS secured approval from the FDA for its first-in-class schizophrenia drug, Cobenfy (xanomeline-trospium).
Sanofi
Company Overview
| Establishment Year | 1973 |
| Headquarter | Paris, France |
| Key Management | Paul Hudson (CEO) |
| Revenue (US$ Bn) | $ 50.2 Billion (2022) |
| Headcount | ~ 86,088 (2023) |
| Website | http://www.sanofi.com/ |
About Sanofi
Sanofi’s efforts in immunology, mental health, and diabetes management support the treatment of bulimia and eating disorder treatment companies.
In 2023, the company acquired Provention Bio, adding TZIELD, a drug aimed at delaying type 1 diabetes onset, which reflects its increasing focus on immune-mediated diseases that may benefit patients with mental health issues related to metabolic and autoimmune disorders.
Furthermore, Sanofi is investing in innovative therapies, including the Dupixent® line, which targets conditions like asthma and atopic dermatitis—disorders often associated with stress and anxiety.
These strategic acquisitions and its expanding pipeline in immunology and neuroscience demonstrate Sanofi’s commitment to health areas connected to mental health, thus supporting adjacent fields like eating disorder treatment.
Geographical Presence
Sanofi S.A., headquartered in Paris, France, is a prominent global healthcare company with operations in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
It has a strong presence in the U.S. and Canada, alongside significant operations in Germany, Italy, and Spain.
In the Asia-Pacific region, growth is particularly notable in China, Japan, and India, while Brazil and Mexico are key markets in Latin America.
Sanofi offers a diverse portfolio that includes diabetes and cardiovascular treatments, vaccines from its Sanofi Pasteur division, and solutions for oncology and rare diseases.
The company focuses on strategic partnerships and local manufacturing to improve healthcare access and meet rising global demands.
Recent Developments
- In October 2024, Sanofi sold a 50% stake in its consumer health business, Opella, to Clayton Dubilier Rice.
- In April 2023, Sanofi acquired Provention Bio, adding TZIELD, a first-in-class type 1 diabetes therapy, to its General Medicines portfolio.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer continues to strengthen its presence in fields like mental health and oncology, which has indirect implications for bulimia and eating disorder treatment companies.
One of the most notable recent developments by Pfizer was the acquisition of Seagen in 2023 for $43 billion, significantly expanding its portfolio in antibody-drug conjugates (ADCs) for cancer treatment.
Although this acquisition primarily focuses on oncology, Pfizer’s growing emphasis on biologics and immunotherapies could eventually have broader applications, including potential mental health benefits, which are often related to eating disorder comorbidities.
Additionally, Pfizer has continued to prioritize R&D and innovation across various therapeutic areas, which may contribute to advancements in treating complex health conditions.
Geographical Presence
Pfizer Inc. is a prominent global biopharmaceutical company with a broad geographical footprint in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
The United States serves as its primary market, significantly contributing to its revenue, along with strong operations in Canada and key European nations like Germany and the UK.
In Asia, Pfizer targets growing markets such as China and Japan while expanding its presence in Latin America, especially Brazil and Mexico.
The company also addresses healthcare challenges in Africa and the Middle East. Through strategic investments, local partnerships, and robust R&D, Pfizer effectively navigates diverse regulatory landscapes and meets global healthcare needs, positioning itself for continued success.
Recent Development
- In October 2024, Pfizer’s ABRYSVO received approval from the FDA for the prevention of lower respiratory tract disease.
- In October 2024, Pfizer partnered with the NFL to become an official pain relief partner of the NFL in Canada.
Teva-Pharmaceutical
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 37,851 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceuticals
Teva Pharmaceuticals has entered the bulimia and eating disorder treatment companies/sector through its presence in neuroscience and related areas that support mental health treatments.
In 2023, Teva launched its “Pivot to Growth” strategy, focusing on expanding its innovative pipeline in key therapeutic areas like neuroscience and immunology.
Teva’s notable products, such as AUSTEDO, used for treating movement disorders, and UZEDY, targeting schizophrenia, reflect the company’s emphasis on neurological and psychiatric conditions.
These advancements could be beneficial in addressing the mental health aspects associated with eating disorders.
Additionally, Teva has been expanding its biosimilar portfolio and investing in late-stage pipeline assets that focus on complex biologics and innovative therapies.
Geographical Presence
Teva Pharmaceuticals, a prominent player in the global pharmaceutical sector, operates in over 60 countries, demonstrating a substantial geographical footprint. In North America, the U.S. and Canada are key markets for its diverse range of generic and specialty medications.
The company maintains a strong presence in both Western and Eastern Europe to meet varied healthcare needs. The Asia-Pacific region, especially Israel, India, China, and Japan, is vital for manufacturing and product expansion.
In Latin America, Brazil and Mexico are significant markets, while Teva is also enhancing its operations in the Middle East and Africa. This extensive network enables Teva to meet regional healthcare demands and solidify its global market position.
Recent Developments
- In October 2024, Teva Pharmaceuticals introduced a generic version of Sandostatin LAR Depot in the US.
- In October 2024, Teva and Alvotech received approval for SELARSDI (ustekinumab-aekn) from the US FDA.
AbbVie
Company Overview
| Establishment Year | 2012 |
| Headquarter | North Chicago, Illinois, United States |
| Key Management | Richard A. Gonzalez (CEO) |
| Revenue (US$ Bn) | $ 50.3 Billion (2023) |
| Headcount | ~ 50,000 (2023) |
| Website | http://abbvie.com/ |
About AbbVie
AbbVie’s recent acquisitions in neuroscience underscore its commitment to mental health, particularly regarding psychiatric conditions relevant to eating disorder treatment.
In 2023, AbbVie acquired Cerevel Therapeutics for $8.7 billion, enhancing its portfolio with assets targeting schizophrenia, Parkinson’s disease, and major depressive disorder, including emraclidine for schizophrenia and tavapadon for Parkinson’s.
Additionally, the acquisition of ImmunoGen provided access to Elahere, an antibody-drug conjugate for ovarian cancer.
These investments reflect AbbVie’s strategy to expand its neuroscience and psychiatric offerings, which may have broader implications for managing mental health, particularly for patients with eating disorders and comorbid conditions such as anxiety and depression.
Geographical Presence
AbbVie Inc. is a global biopharmaceutical company with a significant presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The United States serves as its largest market, complemented by operations in Canada, the UK, Germany, Japan, Brazil, and other regions.
AbbVie focuses on innovative therapies in immunology, oncology, and virology, with major products like Humira and Imbruvica.
The company invests heavily in research and development, collaborates with other firms, and adheres to regulatory standards to enhance market access and capitalize on emerging opportunities in the biopharmaceutical landscape.
Recent Developments
- In October 2024, AbbVie received FDA approval for VYALEV, a 24-hour infusion therapy for motor fluctuations in advanced Parkinson’s disease.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
